ADAPTIMMUNE THERAPEUTICS PLC ADS news, videos and press releases
For more news please use our advanced search feature.
ADAPTIMMUNE THERAPEUTICS PLC ADS - More news...
ADAPTIMMUNE THERAPEUTICS PLC ADS - More news...
- ADAP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Adaptimmune Therapeutics plc Is Fair to Shareholders
- Thinking about buying stock in Leap Therapeutics, Aterian, Hepion Pharmaceuticals, Adaptimmune Therapeutics, or Endo International?
- “The Buzz'' Show: Adaptimmune Therapeutics plc (NASDAQ: ADAP) Strategic Collaboration with Genentech
- Thinking about buying stock in Adaptimmune Therapeutics, Ziopharm Oncology, Uniqure NV, GlycoMimetics, or AbCellera Biologics?
- Adaptimmune Therapeutics plc - ADAP Stock Chart Technical Analysis for 01-14-2020
- Adaptimmune Therapeutics plc - ADAP Stock Chart Technical Analysis for 01-13-2020
- Adaptimmune Therapeutics plc - ADAP Stock Chart Technical Analysis for 05-06-2019
- Adaptimmune Therapeutics plc - ADAP Stock Chart Technical Analysis for 08-24-18
- Report: Exploring Fundamental Drivers Behind Brookfield Property Partners, Grupo Financiero Galicia S.A, Adaptimmune Therapeutics, Radware, Mimecast, and Bandwidth — New Horizons, Emerging Trends, and Upcoming Developments
- Adaptimmune Therapeutics PLC Sponsored ADR to Host Earnings Call
- Adaptimmune Therapeutics
- Adaptimmune confirms GSK Nomination of Second Adaptimmune Target under Strategic Multi-Target Collaboration
- Adaptimmune Announces New Senior Vice President of Global Bio-Process and Development
- Adaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors
- Adaptimmune and Bellicum Pharmaceuticals Enter a Strategic Collaboration to Evaluate Next-Generation T-Cell Therapies
- Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study
- Adaptimmune Announces Update on Clinical Data from NY-ESO SPEAR™ T-cell Synovial Sarcoma Study at the 2016 Annual Meeting of the Connective Tissue Oncology Society (CTOS)
- Adaptimmune Presents Preclinical Data from a New, Wholly-owned SPEAR™ T-cell and a Second Generation SPEAR T-cell at the 31st Annual Meeting of the Society for Immunotherapy for Cancer (SITC)
- Adaptimmune Reports Third Quarter 2016 Financial Results
- Adaptimmune Announces Removal of Partial Clinical Hold in Myxoid/Round Cell Liposarcoma (MRCLS)
- Adaptimmune Announces Appointment of Tal Zaks to Board of Directors
- Adaptimmune to Present Three Posters at the 31st Annual Meeting of the Society for Immunotherapy for Cancer (SITC)
- Adaptimmune to Report Third Quarter 2016 Financial Results on November 10, 2016
- Adaptimmune Announces Board Changes
- Adaptimmune Announces Collaboration with MSD to Evaluate KEYTRUDA® (pembrolizumab) in Combination with NY-ESO SPEAR® T-Cell Therapy in Multiple Myeloma
- Adaptimmune Announces Initiation of Triple Tumor Study to Evaluate its SPEAR® T-Cell Therapy Targeting MAGE-A10
- Adaptimmune Provides Update on Clinical Study Evaluating its SPEAR® T-Cell Therapy Targeting NY-ESO-1 in Ovarian Cancer
- Adaptimmune Provides Update on Study of NY-ESO SPEAR® T-cell Therapy in Synovial Sarcoma at the European Society for Medical Oncology (ESMO) 2016 Congress
- Adaptimmune to Provide Update on Study of NY-ESO SPEAR® T-cell Therapy in Synovial Sarcoma at the European Society for Medical Oncology (ESMO) 2016 Congress